Black Diamond Therapeutics, Inc. (BDTX) Stock

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. is led by CEO Mark A. Velleca, employs 24 people, headquartered in US, publicly traded since 2020.

Black Diamond Therapeutics, Inc. (BDTX) stock trades at $1.88 with a market capitalization of $107.73M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.62, reflecting a net loss over the last twelve months, price-to-book of 1.16, price-to-sales of 1.59. Over the past 52 weeks the stock has ranged between $1.60 and $4.94, and currently trades 61.9% below its 52-week high.

On profitability, Black Diamond Therapeutics, Inc. generates a return on equity (ROE) of -38.80% (negative, reflecting a net loss), return on capital employed of -47.54%, an operating margin of 28.57%, a net profit margin of 31.43%.

Black Diamond Therapeutics, Inc. by the numbers, 2017–2025

Between 2017 and 2025 Black Diamond Therapeutics, Inc. reported revenue of $0 rising to $70.0M. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit rose to $22.0M.

The most recent net margin is 31.43%. On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-42.0M.

Borrowings rose from $12.0M to $19.0M, cash from operations was $30.0M in the latest year, positive in 1 of the last 9.

Return on equity has averaged -55.5% over five years, and was 19.6% in the most recent year.

The share price itself has compounded at -33.1% a year over five years, -4.9% over three, -25.5% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Black Diamond Therapeutics, Inc. (BDTX) — frequently asked questions